Investors Key press releases 18 NOV 2021 13:44 E.S.T. Cytovia and Cellectis Expand Their TALEN® Gene-Edited iNK Partnership to Enable Broader Collaboration in China READ MORE 11 NOV 2021 17:19 E.S.T. Cellectis Presents First Preclinical Data on UCARTMESO, an Allogeneic CAR-T Cell Product Candidate Targeting Mesothelin to Treat Solid Tumors at the Annual Meeting of the Society for Immunotherapy of Cancer READ MORE 04 NOV 2021 14:51 E.S.T. Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2021 READ MORE Key upcoming events 06 DEC 2021 ‐ 07 DEC 2021 The JMP Securities Hematology and Oncology Summit LEARN MORE 11 DEC 2021 ‐ 14 DEC 2021 63rd American Society of Hematology (ASH) LEARN MORE 14 DEC 2021 ‐ 16 DEC 2021 Cell Therapy Analytical Development Summit LEARN MORE Key corporate presentation Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on the Euronext Growth Paris (ticker: ALCLS). Cellectis ADS (Nasdaq) TICKER: CLLS $8.6900 -0.0300 (-0.3440%) PREV. CLOSE 8.7200 VOLUME 81,714 HIGH 8.7850 CAPITALIZATION 395.180M Last Update: about 2 days ago Cellectis (Euronext Growth Paris) TICKER: ALCLS €7.6900 -0.1500 (-1.9133%) PREV. CLOSE 7.8400 VOLUME 96,798 HIGH 7.7900 CAPITALIZATION 349.705M Last Update: 2 days ago SEE STOCK INFORMATION COVERING RESEARCH ANALYSTS Barclays - Gena Wang Citi - Yigal Nochomovitz Goldman Sachs - Salveen Richter& Elisabeth Webster Guggenheim - Michael Schmidt & Kelsey Goodwin Jefferies - Kelly Shi Jones Trading - Soumit Roy Kempen - Ingrid Gafanhão Ladenburg – Wangzhi Li Oddo BHF - Martial Descoutures Oppenheimer – Hartaj Singh Portzamparc – Christophe Dombu RW Baird - Jack Allen Wells Fargo – Nick Abbott William Blair – Raju Prasad CELLECTIS CONTACT INFORMATION Eric Dutang +1 (646) 630 1748 investors@cellectis.com CITIBANK ADR CONTACT INFORMATION Intermediaries & Investors US: +1 212 723 5435 UK: +44 207 500 2030 citiadr@citi.com SOCIÉTÉ GÉNÉRALE SECURITIES SERVICES - ORDINARY SHARES CONTACT INFORMATION Call center in English and French Monday to Friday from 8:30am to 6pm CEST +33 (0)2 51 85 67 89 Get updates Get the latest on gene-editing innovation, financial and business news from Cellectis with our email alert service. SUBSCRIBE NOW LEGAL NOTICEGLOSSARYMEDIA LIBRARYCONTACTCOMMUNITY GUIDELINES Subsidiary: Calyxt Inc.